Guidant makes cuts in endovascular unit
This article was originally published in Clinica
Guidant is to restructure its Endovascular Solutions operations, and will reduce the workforce at some of its California sites by some 200 people. The company says the move is designed to "enhance long-term profitability by aligning its infrastructure with its revenue outlook".
You may also be interested in...
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.